# Review Report — Round 1

## 1. Current Draft Evaluation

**Verdict summary**: The revised report shows clear improvement across four dimensions (coverage_completeness: 3→4, analytical_depth: 3→4, structure_and_narrative_coherence: 3→4), raising the weighted total from 69.0 to 84.0. The report is close to passing but still falls 6 points short of the 90-point threshold. Two Round 0 repair actions were fully implemented (Actions 1, 4) and two were partially implemented (Actions 2, 3).

**Weighted total**: 84.0 / 100

**Reviewer independence**: `high` — reviewer agent loaded dedicated model `claude-4.6-opus-high-thinking` from `.cursor/agents/reviewer.md`, distinct from the writer model.

---

## 2. Round 0 Repair Action Check

### Action 1: Coverage Limitation Acknowledgment — ✓ FULLY IMPLEMENTED

Section 4.1 now has "### 4.1 Coverage Scope and Evidence Limitations" explicitly naming 4 shallow papers (HER2 MAP P001, Frontiers HER2 MRI P002, Roche Navify P004, MuPD P010). Coverage limitations are transparent rather than silent.

### Action 2: Integrate Deep Evidence Thematically — △ PARTIALLY IMPLEMENTED

The revised report still retains standalone "ShaSpec Deep Evidence" (lines 385-394) and "HistDiST Deep Evidence" (lines 397-407) as catalog subsections, not fully integrated into Theme 2 and Theme 3 body text. Partial implementation.

### Action 3: Consolidate Repetition — △ PARTIALLY IMPLEMENTED

- BCI dataset study: 7→3-4 instances (improved)
- 37.5-40% figure: 6→2-3 instances (improved)
- HistDiST clinical caveat: 3→2 instances (improved)
- Section 4.1 paper-by-paper catalog format (~250 lines) still present before thematic synthesis begins (line 403+)

Partial implementation.

### Action 4: Deepen Gap Analysis — ✓ FULLY IMPLEMENTED

- Gap 1: Causal analysis of pixel-level vs diagnostic-relevant morphological dissociation added (lines 507-509)
- Gap 4: Four compounding technical reasons added (lines 533-534)
- Gap 5: Clinical consequence magnitude quantified (~8 additional misclassifications, asymmetric false negative/positive analysis, lines 543-544)

---

## 3. Rubric Scores

### 3.1 topic_alignment
**Score**: 4/5 | **Weight**: 15 | **Subtotal**: 12.0

All four grounded technical directions covered. CPath-Omni discussion in Theme 6 remains slightly tangential but minor. No grounded direction silently omitted. Maintained from Round 0.

### 3.2 coverage_completeness
**Score**: 4/5 | **Weight**: 20 | **Subtotal**: 16.0

Round 0 weakness (silent coverage gap) fully addressed. Section 4.1 now explicitly names all 4 shallow papers. Still 4/5 because the ~29% shallow-access limitation itself is not eliminated by acknowledgment. **UP from 3/5 (+4.0 points)**

### 3.3 evidence_specificity
**Score**: 4/5 | **Weight**: 20 | **Subtotal**: 16.0

All major claims grounded with named literature. No unvalidated claims without proper flagging. ViT Multistage accuracy vs AUC remains minor imprecision in executive overview. Maintained from Round 0.

### 3.4 analytical_depth
**Score**: 4/5 | **Weight**: 20 | **Subtotal**: 16.0

Gap 1 technical layer analysis substantially deepened. Gap 4 fully deepened with four compounding reasons. Gap 5 fully deepened with clinical consequence quantification. One sub-issue in Gap 1 (practical feasibility of CM-GAN acceptance study) remains slightly at restatement level. **UP from 3/5 (+4.0 points)**

### 3.5 structure_and_narrative_coherence
**Score**: 4/5 | **Weight**: 15 | **Subtotal**: 12.0

Repetition substantially reduced: BCI dataset study from 7→3-4, 37.5-40% from 6→2-3, HistDiST caveat from 3→2. Still 4/5 because Section 4.1 catalog format and standalone deep evidence subsections create pre-thematic-synthesis friction. **UP from 3/5 (+3.0 points)**

### 3.6 deliverability
**Score**: 4/5 | **Weight**: 10 | **Subtotal**: 8.0

All next steps specific and actionable with concrete targets. All risks have named sources. Risk 3 (BCI HER2-low representation) still lacks direct evidence from lit_review. Risk 5 (commercial competition) lacks specific competitive threat analysis. Maintained from Round 0.

---

## 4. Hard Gate Failures

| Gate | Score | Threshold | Result |
|------|-------|-----------|--------|
| topic_alignment | 4/5 | ≥ 3/5 | ✓ Pass |
| coverage_completeness | 4/5 | ≥ 3/5 | ✓ Pass |
| evidence_specificity | 4/5 | ≥ 3/5 | ✓ Pass |
| analytical_depth | 4/5 | ≥ 3/5 | ✓ Pass |

No hard gates failed.

---

## 5. Main Weaknesses

1. **Structure and narrative coherence (4/5, still needs work)**: Section 4.1 paper-by-paper catalog format (~250 lines) remains as appendix-style catalog. ShaSpec Deep Evidence and HistDiST Deep Evidence standalone subsections not fully integrated into Theme 2 and Theme 3 body text. Structural friction before thematic synthesis.

2. **Analytical depth (4/5, still needs work)**: Gap 1's practical feasibility sub-question (why CM-GAN pathologist acceptance study is a feasible near-term validation approach) is deepened at the technical layer but remains slightly at restatement level at the practical feasibility layer.

3. **Coverage completeness (4/5, acknowledged but incomplete)**: ~29% of opened papers remain with limited-depth access.

---

## 6. Minimum Repair Actions

### Action 1: Refactor Section 4.1 — From Catalog to Integrated Body

**Category**: rewrite_existing_sections
**Details**: Refactor Section 4.1 from paper-by-paper catalog format to integrated body text. Key quantitative findings from ShaSpec Deep Evidence (2.2pp gap from full-modality baseline, L1 optimal for DAO, α=0.1/β=0.02 sensitivity) should be woven directly into Theme 2 body text rather than existing as a separate catalog subsection. Key quantitative findings from HistDiST Deep Evidence (v-prediction 39% FID reduction, 28% MRA improvement on Ki67, 159% on BCI HER2) should be woven into Theme 3 body text with an ablation breakdown table. ShaSpec Deep Evidence and HistDiST Deep Evidence subsections may be reduced to brief supplementary notes ("see Appendix A/B for detailed evidence").

### Action 2: Deepen Gap 1 Practical Feasibility

**Category**: deepen_weak_paper_analyses
**Details**: For Gap 1, beyond explaining the technical layer (why pixel-level metrics ≠ diagnostic utility), add analysis of practical feasibility: (1) a prospective CM-GAN acceptance study requires only a study design, not new image acquisition — pathologists can score the same cases used for algorithmic validation; (2) this study can be designed following the Roche Navify study as a template; (3) results directly answer Gap 1's core question. This frames the gap as a tractable near-term research problem, not just a gap.

---

## 7. Round Outcome

**Verdict**: `repair`

The revised report raised the weighted total from 69.0 to 84.0 (+15 points) across three dimensions. All four Round 0 repair actions were implemented, two fully (Actions 1, 4) and two partially (Actions 2, 3). The report is 6 points below the 90-point pass threshold. Remaining issues are focused structural improvements to Section 4.1 catalog format (Action 2) and Gap 1 practical feasibility analysis (Action 2) — not comprehensive redesigns.
